156 related articles for article (PubMed ID: 35918032)
1. Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae.
Lan P; Lu Y; Jiang Y; Wu X; Yu Y; Zhou J
Int J Antimicrob Agents; 2022 Oct; 60(4):106646. PubMed ID: 35918032
[TBL] [Abstract][Full Text] [Related]
2.
McElheny CL; Fowler EL; Iovleva A; Shields RK; Doi Y
Microbiol Spectr; 2021 Dec; 9(3):e0177921. PubMed ID: 34756080
[TBL] [Abstract][Full Text] [Related]
3. Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China.
Lan P; Lu Y; Chen Z; Wu X; Hua X; Jiang Y; Zhou J; Yu Y
Microbiol Spectr; 2022 Apr; 10(2):e0008422. PubMed ID: 35323031
[TBL] [Abstract][Full Text] [Related]
4. Elucidating the effect of iron acquisition systems in Klebsiella pneumoniae on susceptibility to the novel siderophore-cephalosporin cefiderocol.
Daoud L; Al-Marzooq F; Moubareck CA; Ghazawi A; Collyns T
PLoS One; 2022; 17(12):e0277946. PubMed ID: 36580460
[TBL] [Abstract][Full Text] [Related]
5. Cefiderocol heteroresistance in Klebsiella pneumoniae is linked to mutations in the siderophore receptor cirA and β-lactamase activities.
Moon SH; Udaondo Z; Jun SR; Huang E
Int J Antimicrob Agents; 2022 Sep; 60(3):106635. PubMed ID: 35820535
[No Abstract] [Full Text] [Related]
6. Extreme resistance to the novel siderophore-cephalosporin cefiderocol in an extensively drug-resistant Klebsiella pneumoniae strain causing fatal pneumonia with sepsis: genomic analysis and synergistic combinations for resistance reversal.
Daoud L; Allam M; Collyns T; Ghazawi A; Saleem A; Al-Marzooq F
Eur J Clin Microbiol Infect Dis; 2023 Nov; 42(11):1395-1400. PubMed ID: 37828413
[TBL] [Abstract][Full Text] [Related]
7. High efficacy and enhanced synergistic activity of the novel siderophore-cephalosporin cefiderocol against multidrug-resistant and extensively drug-resistant Klebsiella pneumoniae from inpatients attending a single hospital in the United Arab Emirates.
Daoud L; Al-Marzooq F; Ghazawi A; Anes F; Collyns T
J Infect Public Health; 2023 Dec; 16 Suppl 1():33-44. PubMed ID: 37953111
[TBL] [Abstract][Full Text] [Related]
8.
Ito A; Sato T; Ota M; Takemura M; Nishikawa T; Toba S; Kohira N; Miyagawa S; Ishibashi N; Matsumoto S; Nakamura R; Tsuji M; Yamano Y
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061741
[TBL] [Abstract][Full Text] [Related]
9. Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA.
Klein S; Boutin S; Kocer K; Fiedler MO; Störzinger D; Weigand MA; Tan B; Richter D; Rupp C; Mieth M; Mehrabi A; Hackert T; Zimmermann S; Heeg K; Nurjadi D
Clin Infect Dis; 2022 Mar; 74(5):905-908. PubMed ID: 34079986
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of cefiderocol-resistant spontaneous mutant variants of Klebsiella pneumoniae-producing NDM-5 with a single mutation in cirA.
Mezcord V; Traglia GM; Pasteran F; Escalante J; Lopez C; Wong O; Rojas L; Marshall SH; Tolmasky ME; Bonomo RA; Ramirez MS
Int J Antimicrob Agents; 2024 May; 63(5):107131. PubMed ID: 38432605
[No Abstract] [Full Text] [Related]
11. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
[TBL] [Abstract][Full Text] [Related]
14. Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible
Burnard D; Robertson G; Henderson A; Falconer C; Bauer MJ; Cottrell K; Gassiep I; Norton R; Paterson DL; Harris PNA
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168603
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.
Sato T; Yamawaki K
Clin Infect Dis; 2019 Nov; 69(Suppl 7):S538-S543. PubMed ID: 31724047
[TBL] [Abstract][Full Text] [Related]
16. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Lee YR; Yeo S
Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
[TBL] [Abstract][Full Text] [Related]
17. Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa.
Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
Pharmacology; 2018; 101(5-6):278-284. PubMed ID: 29471305
[TBL] [Abstract][Full Text] [Related]
18. In vivo evolution to high-level cefiderocol resistance of NDM-1-producing Klebsiella pneumoniae, followed by intra-hospital cross-transmission.
Tascini C; Coppi M; Antonelli A; Niccolai C; Bartolini A; Pecori D; Sartor A; Giani T; Rossolini GM
Clin Microbiol Infect; 2024 Mar; 30(3):398-400. PubMed ID: 37979689
[No Abstract] [Full Text] [Related]
19. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
20.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
